Wockhardt Ltd (Wockhardt) is a pharmaceutical and biotechnology company that develops, manufactures, and commercializes finished formulations, active pharmaceutical ingredients (APIs), biological drug substances and aseptic biological drug products. The company operates in the US, the UK, Ireland, Switzerland, Russia, Mexico, and India.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Wockhardt has been actively engaged in R&D initiatives focusing on discovering effective antibacterial solutions to combat antimicrobial resistance (AMR). The company has developed a robust pipeline of novel antibiotics, with three already launched and three at various stages of clinical development. Wockhardt has received qualified infectious disease product (QIDP) status from the US FDA for several of its drugs, highlighting its commitment to addressing global health challenges. The company has also invested significantly in R&D infrastructure, with facilities in India, the US, the UK, and the UAE, and has filed numerous patents to protect its innovations. It operates dedicated, state-of-the-art research and development facilities in India and the UK. These units are responsible for managing the company's R&D activities, including discovery research, new chemical entity (NCE) development, and clinical studies. The R&D units focus on developing novel antibiotics, biosimilars, and other pharmaceutical products to address unmet medical needs. As of March, 2026, the company has filed 3,290 cumulative patents and has been granted 859 patents. Wockhardt's pipeline includes several novel antibiotics and other pharmaceutical products, with a strong focus on addressing AMR.